Merck (MRK) to Buy Curon’s Bispecific Antibody Drug for $1.3B
ZacksMerck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is expected to close by third-quarter 2024.